论文部分内容阅读
1979年9月29日在荷兰Leiden举行的“欧洲移植”会议上,对于如何提高肾移植的存活率是会议的中心议题之一。会上报告的有关移植免疫方面的几个问题,是国外较新的研究动态。一、关于HLA-DR配型在无亲缘关系的肾移植中,使用混合淋巴细胞培养方法(MLC),挑选MLC阴性或刺激指数低的供受对,可得到较好的移植效果;但这个方法化时较长,而且只适用于活供体。1979年9月在英国牛津举行的第七次国际组织相容性试验专题讨论会上,鉴于B淋巴细胞抗原和HLA-D位点所控制的决定簇之间存在着紧密相关,而被命名为HLA-DR抗原。它是用血清学方法鉴定的,这就有可能对尸肾供体和受体作HLA-DR配型。实践表明HLA-DR配型比HLA-A、-B配型更为理想。一个DR相配合的6个月存活率(80％)相当于HLA-A,-B抗原完全相配合的
At the European Transplant Conference held in Leiden, the Netherlands, on September 29, 1979, one of the central topics of the meeting was how to improve the survival rate of kidney transplantation. A few questions about transplantation immunity reported at the meeting are the latest research developments in foreign countries. First, on the HLA-DR typing in unrelated renal transplantation, the use of mixed lymphocyte culture (MLC), the selection of MLC negative or stimulation index low for the right, can be a better transplant effect; but this method Longer time, but only for living donors. At the Seventh Symposium on the International Organizational Compatibility Test held in Oxford, England, in September 1979, given the close relationship between the B lymphocyte antigen and the determinants controlled by the HLA-D locus, HLA-DR antigen. It is identified by serological methods, making it possible to HLA-DR matching donor and recipient corpse. Practice shows that HLA-DR typing than HLA-A, -B matching is more ideal. A DR-matched 6-month survival rate (80%) corresponds to a complete match of the HLA-A and -B antigens